Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront
2 days ago
China
AI
Novo Nordisk plans Phase 3 trials of oral, injectable amycretin for early 2026
2 days ago
Pharma
Exclusive: Kennedy picks for vaccine advisory board were paid experts against Merck in civil cases
2 days ago
Pharma
FDA+
Insmed aims to raise $750M in one of the largest stock offerings this year
3 days ago
Financing
Kura, Kyowa say Phase 1 update supports menin inhibitor combos
3 days ago
Schrödinger says early MALT1 data could lay 'great foundation' for combos
3 days ago
Exclusive: Organoid startup raises $21M to test drugs and vaccines in human lymph nodes-in-a-dish
3 days ago
Startups
House appropriators call for FDA tweaks on accelerated approvals, biosimilars
3 days ago
FDA+
Watch Post-Hoc Live: What happens when AI thinks in ways we can’t understand?
3 days ago
Editor's note
AI
Cabaletta Bio shares CAR-T results in three autoimmune conditions
4 days ago
Vaxart shares surge on norovirus vaccine data as it seeks funding for new trials
4 days ago
BMS’ RayzeBio inks radiopharma deal in prostate cancer for $350M upfront
4 days ago
Deals
Argenx says its drug Vyvgart looks promising in two more autoimmune diseases
4 days ago
Pharma
FDA’s Makary says he wasn’t part of decision to gut ACIP, defers possible VRBPAC changes to Prasad
4 days ago
Pharma
FDA+
FDA places hold on Gilead's studies of HIV treatment pill combo
5 days ago
FDA+
Exclusive: Rebooting dead human brains, a biotech startup seeks to reinvent early drug testing work
5 days ago
In Focus
Updated: Merck wins FDA approval for RSV antibody drug, making a hot market more competitive
5 days ago
Pharma
FDA+
Federally-funded cancer research comes to a perilous crossroads
5 days ago
Bioregnum
Merck says its oral PCSK9 inhibitor ‘significantly’ cut cholesterol in two Phase 3 trials
6 days ago
NewAmsterdam's experimental cholesterol drug reduces presence of Alzheimer's biomarker
6 days ago
Metsera shares early data on anti-obesity amylin candidate
6 days ago
Startups
Is there still hope for Summit's cancer drug buried in the data?
Last week
Otsuka spells out Phase 3 win in rare kidney disease, Vera’s stock takes a hit
Last week
A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation
Last week
Pharma
1
2
3
4
Next page
Last page